Please activate JavaScript!
Please install Adobe Flash Player, click here for download


REFERENCES 1. An P., Bleiber G., Duggal P., Nelson G., May M., Mangeat B., Alobwede I., Trono D., Donfield S., Goedert J.J., Phair J., Vlahov D., O’Brien S.J., Telenti A., Winkler C., 2004. APOBEC3G genetic variants and their influence on AIDS. J Virol 78. 2. Back N.K.T., Berkhout B., 1997. Limiting deoxynucleoside triphosphate concentra- tions emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 41:2484–2491. 3. Back N.K.T., Nijhuis M., Keulen W., Boucher C.A.B., Oude Essink B.B., van Kuilenburg A.B.P., van Gennip A.H., Berkhout B., 1996. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 15:4040–4049. 4. Bally F., Martinez R., Peters S., Sudre P., Telenti A., 2000. Polymorphism of HIV-1 Gag p7/p1 and p1/p6 cleavage sites. Clinical significance and implications for resist- ance to protease inhibitors. AIDS Res Hum Retrovir 16:1209–1213. 5. Bleiber G., May M., Bashirova A., Ang P., Martinez R., Ortiz M., Meylan P., Winkler C., O’Brien S.J., Ott J., Beckmann J., Carrington M., Telenti A., 2004. Screening and modeling of new HIV-1 restriction alleles using a combined in vitro / in vivo popu- lation approach. In draft. 6. Bleiber G., Munoz M., Ciuffi A., Meylan P., Telenti A., 2001a. Individual contribu- tion of protease and reverse transcriptase to infectivity, replication and protein matu- ration of antiretroviral drug resistant human immunodeficiency virus type 1. J Virol 75:3291–3300. 7. Bleiber G., Telenti A., 2001b. Fitness of HIV-1 strains resistant to antiretroviral drugs. International Antiviral News 9:146–149. 8. Borman A.M., Clavel F., 1996. Resistance to human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J Gen Virol 77:419–426. 25